Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, July 2, 2021
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
[ Fri, Jul 02nd 2021
] - WOPRAI
Thu, July 1, 2021
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
[ Thu, Jul 01st 2021
] - WOPRAI
Zhiqiang Shu Downgraded (SNSE) to Hold and Held Target at $12 on, Jul 1st, 2021
Zhiqiang Shu of Berenberg, Downgraded "Sensei Biotherapeutics, Inc." (SNSE) to Hold and Held Target at $12 on, Jul 1st, 2021.
Zhiqiang has made no other calls on SNSE in the last 4 months.
There are 2 other peers that have a rating on SNSE. Out of the 2 peers that are also analyzing SNSE, 1 agrees with Zhiqiang's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kevin DeGeeter of "Oppenheimer" Downgraded from Buy to Hold on, Tuesday, June 29th, 2021
This is the rating of the analyst that currently disagrees with Zhiqiang
- Joseph Catanzaro of "Piper Sandler" Initiated at Buy and Held Target at $25 on, Monday, March 1st, 2021
